Lyell Immunopharma, Inc. Profile Avatar - Palmy Investing

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…

Biotechnology
US, South San Francisco [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of LYEL's Analysis
CIK: 1806952 CUSIP: 55083R104 ISIN: US55083R1041 LEI: - UEI: -
Secondary Listings
LYEL has no secondary listings inside our databases.